$DHR (Danaher Corp.)

$DHR {{ '2016-04-21T11:21:21+0000' | timeago}} • Announcement

$DHR President and CEO Thomas Joyce, Jr. stated, "We were pleased with our start to 2016 as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high-teens earnings growth, healthy operating margin expansion and free cash flow that was up over 50% year-on-year."

$DHR {{ '2017-09-12T20:31:22+0000' | timeago}} • Announcement

$DHR said its BoD declared a regular quarterly dividend of $0.14 per share. The dividend is payable on October 27, 2017 to shareholders of record on September 29, 2017.

$DHR {{ '2017-07-20T15:06:40+0000' | timeago}} • Webcast

With nearly $900MM of free cash flow and strong conversion in 2Q17, $DHR is optimistic on further acqusitions. Adding to its strong cash flow, $DHR has $500MM to $1Bil worth of opportunities slated for 2H17. Notably, the company's two most recent large acquisitions, Pall and Cepheid, continues to perform well and became part of the core revenue.

$DHR {{ '2017-07-20T13:00:10+0000' | timeago}} • Announcement

For 3Q17, $DHR sees its GAAP EPS to range from $0.74 to $0.78 and non-GAAP EPS to range from $0.92 to $0.96. For FY17, GAAP EPS to range from $3.16 to $3.23 and non-GAAP EPS to range from $3.90 to $3.97.

$DHR {{ '2017-07-20T12:56:52+0000' | timeago}} • Announcement

$DHR, a science and technology company, reported a 15% YoY drop in net earnings for 2Q17 to $557.3MM, or $0.79 per share. Earnings, adjusted for one-time gains and costs, grew 10% to $0.99 per share. Sales rose 6% to $4.5Bil.

$DHR {{ '2017-07-20T12:12:31+0000' | timeago}} • Infographic

$DHR Danaher Corp. Earnings AlphaGraphic: Q2 2017 Highlights

$DHR {{ '2017-06-20T13:47:35+0000' | timeago}} • Announcement

$DHR's subsidiary DH Europe Finance priced an offering of EUR250MM of floating rate senior notes due 2022 at an offering price of 100.147% of the principal amount; and EUR600MM of 1.200% senior notes due 2027 at an offering price of 99.682% of the principal amount. The offering is expected to close on June 30, 2017.

$DHR {{ '2017-04-20T12:58:57+0000' | timeago}} • Webcast

$DHR is confident about its position in China across all of its five platforms and the opportunities ahead for sustained double-digit growth performance. Dental business continues to drive consistent double-digit growth in each quarter for quite sometime. $DHR added that water quality business had good performance so far this year in China.

$DHR {{ '2017-04-20T10:21:58+0000' | timeago}} • Announcement

$DHR expects 2Q17 EPS of $0.77-0.80 and adjusted EPS of $0.95-0.98. For 2017, the company still sees EPS of $3.13-3.23 and adjusted EPS of $3.85-3.95. Through focused execution across the portfolio, and with Business System continuing to serve as foundation, $DHR sees tremendous opportunities to deliver long-term value creation.

$DHR {{ '2017-04-20T10:19:32+0000' | timeago}} • Announcement

$DHR reported a drop in 1Q17 earnings hurt by higher costs and expenses as well as last year's gain on sale of investments. Net income fell to $506.1MM or $0.72 per share from $758.4MM or $1.09 per share last year. Sales grew to $4.21Bil from $3.92Bil. Adjusted EPS increased to $0.85 from $0.79.

$DHR {{ '2017-02-22T12:54:51+0000' | timeago}} • Announcement

$DHR said it has appointed Raymond Stevens to its BoD. Stevens is currently Provost Professor of Biological Sciences and Chemistry, and Director of The Bridge Institute, at the University of Southern California.

$DHR {{ '2017-01-31T19:38:32+0000' | timeago}} • Webcast

In Life Sciences, $DHR’s reported revenue was up 6% and core revenue grew 4% during 4Q16. In Diagnostics, reported revenue increased 11% and core revenue increased 3%. In the Dental segment, reported and core revenues increased 50BP. In Environmental & Applied Solutions, reported revenue grew 3.5% with core revenue up 4%.

$DHR {{ '2017-01-31T19:28:14+0000' | timeago}} • Webcast

In 4Q16, $DHR’s sales grew 6% with core revenue increasing 3.5%. The impact of currency translation decreased revenues by 1.5% while acquisitions increased revenues by 4%. High-growth markets revenue was up high single digits. Developed market core revenues were up low single digits, led by growth in the US and Western Europe.

$DHR {{ '2017-01-31T14:15:10+0000' | timeago}} • Announcement

$DHR expects 1Q17 EPS of $0.64-0.67 and adjusted EPS of $0.82-0.85. For the full year 2017, $DHR predicts EPS of $3.13-3.23 and adjusted EPS of $3.85-3.95.

$DHR {{ '2017-01-31T14:13:26+0000' | timeago}} • Announcement

$DHR reported a rise in 4Q16 earnings driven by higher sales, and meaningful margin expansion. Net income rose to $747MM or $1.07 per share from $688.6MM or $0.99 per share last year. Sales grew to $4.58Bil from $4.32Bil. Adjusted EPS increased 15.5% to $1.05.

$DHR {{ '2016-12-15T14:21:14+0000' | timeago}} • Announcement

$DHR said it anticipates its FY17 diluted net EPS to be about $3.13 to 3.23. The company expects its non-GAAP adjusted net EPS to be about $3.85 to 3.95, which assumes non-GAAP core revenue growth to be about 3-4%.

$DHR {{ '2016-12-01T14:35:52+0000' | timeago}} • Announcement

$DHR promoted Rainer Blair to EVP, with responsibility for the company's $5Bil Life Sciences platform, effective Jan. 1, 2017. In his new role, Blair will report directly to CEO Thomas Joyce Jr.

$NDSN {{ '2016-11-28T14:25:50+0000' | timeago}} • Announcement

The BoD of $NDSN has elected Stephen P. Lovass as Corporate Vice President for its Industrial Coating Systems (ICS) business segment. He succeeds Douglas C. Bloomfield who will retire at the end of 2016. Mr. Lovass joins $NDSN from $DHR and he has also previously worked with Gerber Scientific Inc.

$DHR {{ '2016-11-07T12:04:18+0000' | timeago}} • Announcement

$DHR closed purchase of $CPHD. Copper Merger Sub, a subsidiary of $DHR, has merged into $CPHD and $CPHD has become an indirect wholly owned subsidiary of $DHR. $CPHD's common stock will cease to be traded on Nasdaq Stock Market.

$FTV {{ '2016-10-27T22:15:00+0000' | timeago}} • Announcement

$FTV, the diversified industrial growth company that operated as part of $DHR prior to July 2, 2016, reported a jump in 3Q16 earnings on higher sales. Net income rose to $226.9MM or $0.65 per share from $196.6MM or $0.57 per share last year. Sales grew 2.8% to $1.57Bil. Adjusted earnings were $233.1MM or $0.67 for 3Q16.

$DHR {{ '2016-10-20T11:36:30+0000' | timeago}} • Announcement

$DHR forecast 4Q16 earnings of $0.85 to $0.89. For the full year 2016, the company anticipates EPS to be $2.86 to $2.90. $DHR said its recent acquisitions of Cepheid and Phenomenex will boost its Diagnostics and Life Sciences segments, respectively, thus enhancing its positioning and broadening the product offerings.

Recent Transcripts

BMI (Badger Meter Inc.)
Tuesday, October 17 2017 - 3:00pm
ATU (Actuant Corporation)
Wednesday, September 27 2017 - 3:00pm
AZO (AutoZone, Inc.)
Tuesday, September 19 2017 - 2:00pm
BGG (Briggs & Stratton Corporation)
Thursday, August 17 2017 - 2:00pm
CAE (CAE Inc.)
Thursday, August 10 2017 - 5:30pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
ZBRA (Zebra Technologies Corporation)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
CCS (Century Communities Inc)
Thursday, August 3 2017 - 9:00pm
FLT (FleetCor Technologies, Inc.)
Thursday, August 3 2017 - 9:00pm
ALG (Alamo Group, Inc.)
Thursday, August 3 2017 - 3:00pm
BLDP (Ballard Power Systems Inc.)
Thursday, August 3 2017 - 3:00pm
BZH (Beazer Homes USA Inc.)
Tuesday, August 1 2017 - 9:00pm
CGNX (Cognex Corporation)
Monday, July 31 2017 - 9:00pm
ROP (Roper Technologies, Inc.)
Monday, July 31 2017 - 12:30pm
B (Barnes Group Inc.)
Friday, July 28 2017 - 12:30pm
CRR (CARBO Ceramics Inc.)
Thursday, July 27 2017 - 3:30pm
BC (Brunswick Corporation)
Thursday, July 27 2017 - 3:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
AGCO (AGCO Corporation)
Thursday, July 27 2017 - 2:00pm

AlphaGraphics you may like